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Inappropriate MET tyrosine kinase receptor sig-
naling is detected in almost all types of human
cancer and contributes to malignant growth and
MET dependency via proliferative and antiapop-
totic activities. Independently, Tensin-4 (TNS4) is
emerging as a putative oncogene in many cancer
types, but the mechanisms of TNS4 oncogenic
activity are not well established. Here, we demon-
strate that TNS4 directly interacts with phos-
phorylated MET via the TNS4 SH2-domain to
positively regulate cell survival, proliferation, and
migration, through increased MET protein stability.
In addition, TNS4 interaction with b1-integrin cyto-
plasmic tail positively regulates b1-integrin stability.
Loss of TNS4 or disruption of MET-TNS4 interac-
tion triggers MET trafficking toward the lysosomal
compartment that is associated with excessive
degradation of MET and triggers MET-addicted car-
cinoma cell death in vitro and in vivo. Significant
correlation between MET and TNS4 expression in
human colon carcinoma and ovarian carcinoma
suggests TNS4 plays a critical role in MET stability
in cancer.
INTRODUCTION
The receptor tyrosine kinase (RTK) MET is activated by its
ligand the hepatocyte growth factor (HGF) and is a potent
regulator of morphogenesis and migration, during development
and in response to tissue injury in the adult (Trusolino et al.,
2010). MET activation induced by receptor overexpression,
genetic amplification (Houldsworth et al., 1990), mutation (Pe-
schard et al., 2001), or increased HGF secretion (Rong et al.,
1994; Straussman et al., 2012) is frequently observed in
cancer cells. HGF stimulation results in MET activation and
subsequent phosphorylation of key tyrosine residues thatDeveregulate the recruitment of adaptor proteins (Trusolino et al.,
2010), MET internalization (Peschard et al., 2001), transient
endosomal signaling (Kermorgant et al., 2004), and MET
receptor trafficking toward either degradation (Hammond
et al., 2001) or recycling back to the membrane (Hammond
et al., 2003; Parachoniak et al., 2011). In cancer, activating
mutations in MET (Joffre et al., 2011) or gain-of-function
mutants of p53 (Muller et al., 2013) induce sustained MET
recycling, promoting tumorigenesis and invasion. Therefore, a
better understanding of the mechanisms regulating MET turn-
over is critical.
RTK signaling is adhesion dependent under normal condi-
tions, and crosstalk between integrin cell-adhesion receptors
and RTKs, including MET, is well established (Ivaska and
Heino, 2011; Lai et al., 2009). Tensins, a family of four scaf-
folding proteins (TNS1, TNS2, TNS3, and TNS4), are emerging
as important regulators of cell motility and growth (Qian et al.,
2009). Tensins 1–3 link integrins to actin via their PTB domains
(Calderwood et al., 2003) and are important components of
fibrillar adhesions (Clark et al., 2010; McCleverty et al., 2007).
Interestingly, unlike other tensins, TNS4 expression is restricted
within normal tissue (Chen et al., 2013; Lo and Lo, 2002).
TNS4 promotes cell migration by triggering the uncoupling
of integrins from the actin cytoskeleton (Katz et al., 2007) and
is emerging as a putative oncogene in many cancer types
(Albasri et al., 2009; Katz et al., 2007; Liao et al., 2009; Saka-
shita et al., 2008; Sasaki et al., 2003a, 2003b). However, the
mechanisms underlying the oncogenicity of TNS4 are poorly
described. All tensins are known to interact via their SH2
domains with tyrosine-phosphorylated cytoplasmic signaling
molecules (Lo, 2007), such as FAK, PI3K, and p130Cas, but
the functional relevance of these interactions is not fully eluci-
dated (Cui et al., 2004; Defilippi et al., 2006; Mitra and Schlaep-
fer, 2006).
Here, we show a direct, tyrosine phosphorylation-dependent
interaction between MET and TNS4 that occurs through the
TNS4 SH2 domain and inhibits MET endocytosis and subse-
quent lysosomal degradation. TNS4 also regulates b1-integrin
stability, MET-dependent cell migration, proliferation, and sur-
vival in vitro and functions as a critical determinant of ‘‘MET-
addicted tumor’’ viability in vivo.lopmental Cell 29, 421–436, May 27, 2014 ª2014 Elsevier Inc. 421
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Gene Name # of clones SID /functional domains
GAB1 20 AA 460-516 /MBD (Met binding domain)
GRB2 14 AA 57-216 /SH2 and C-terminal SH3
PLCG1 19 AA 616-662 /SH2
PIK3R1 variant 1 21 AA 411-498 /SH2
TNS3 5 AA 1135-1356 /SH2
TNS4 4 AA 416-624 /SH2
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Tensin Isoforms 3 and 4 Associate with Active MET
Yeast two-hybrid screens using a truncated intracellular version
ofMET (containing its kinase domain) as bait revealed an interac-
tion between tensin isoforms 3 and 4 and MET (Figure 1A).
Several of the well-defined MET-interacting proteins (PI3K,
GAB1, and GRB2 protein isoforms) were also identified, thus
validating the approach. TNS3-GFP and TNS4-GFP, but not
GFP alone, coimmunoprecipitated with overexpressed MET in
HEK293 cells (Figure 1B). This interaction did not require HGF
stimulation as the transiently overexpressed MET is constitu-
tively phosphorylated in HEK293 cells, due to high expression
levels (Figure S1A available online; note that both bands de-
tected in the overexpressing cells represent phosphorylated
MET bands). TNS4, unlike TNS3, lacks an actin-binding domain
(Figure S1B) and has been suggested to possess oncogenic
functions inmany cancer types. This notion was further validated
by our analysis of publicly accessible microarray data for
changes in TNS3 and TNS4 gene expression. In colorectal,
lung, ovarian, and gastric cancers, TNS4 was significantly upre-
gulated with concomitant downregulation of TNS3 levels (Fig-
ure S1C) compared to normal tissue. Focusing on TNS4, we
further confirmed that the association with MET was dependent
onMET kinase activity (Figures 1C and 1D). TNS4-GFP coimmu-
noprecipitated phosphorylated MET, whereas expression of a
kinase-dead mutant of MET (MET KD) or wild-type (WT) MET
(MET WT) in combination with three different specific MET kinase
inhibitors abolished TNS4-MET association. Consistent with
the recruitment of TNS4 to MET in a phosphorylation-dependent
manner, coimmunoprecipitation of endogenous MET and TNS4
(Figure 1E) was observed in GTL-16 gastric carcinoma cells
harboring MET amplification and high levels of constitutively
active MET. In A549 lung carcinoma cells, endogenous MET
overlapped with TNS3-GFP, confirming their ability to associate
as shown above (Figure S1D). Endogenous MET and TNS4-GFP
(Figure 1F) localized to the same membrane structures and ex-
hibited a significant increase in colocalization following HGF
stimulation (Figure 1F and GFP-transfected control cells Fig-
ure S1E). Furthermore, endogenous TNS4 and MET overlapped
in paxillin-positive adhesion sites (Figure 1G).
Active MET Binding to TNS4 SH2 Domain Requires the
R474 Residue
To better define the TNS4-MET association, we generated a
TNS4 C-terminal construct containing only the TNS4 SH2 andFigure 1. MET Associates with TNS3 and TNS4
(A) TNS3 and TNS4 were identified as putative MET interactors in a yeast two-hyb
(selected interactiondomain) indicates thecommonaminoacid sequence thatbinds
(B) GFP-TRAP pull-down in HEK293 cells cotransfected with MET and GFP or T
(C) GFP-TRAP pull-down in HEK293 cells cotransfected with TNS4-GFP and ME
(D) GFP-TRAP pull-down in HEK293 cells cotransfected with TNS4-GFP and M
(SU1174, 5 mM), or INCB (INCB28060, 2 mM) for 16 hr.
(E) Endogenous MET immunoprecipitation from GTL-16 cell extracts compared
(F) Representative single channel andmerged images of TNS4-GFP andMET stai
(30 ng/ml, for 30 min) A549 cells expressing TNS4-GFP. r = Pearson’s correlation
cells from three independent experiments; statistical significance was analyzed
(G) Representative single channel and merged images of control and HGF-treate
MET (antibody directed against extracellular domain). Insets highlight regions of
DevePTB domains (Figure 2A) and expressed this as a recombinant
glutathione S-transferase (GST) fusion protein (Figure S2A). In
pull-downs, a GST-TNS4-SH2-PTB fragment (but not GST
alone; Figure S2B) was sufficient to pull down MET from HGF-
responsive A549 cells (Figures 2B and 2C) with low basal HGF
secretion (Figure S2C) and MET activity and from GTL-16 cells
withMET amplification and high levels of the constitutively phos-
phorylated MET receptor (Figures 2B and 2C). TNS4-MET bind-
ingwas dependent onMET activity; bindingwas induced byHGF
stimulation in A549 cells and reduced in GTL-16 cells upon MET
kinase inhibition (Figure 2C).
Next, we sought to identify the TNS4 MET binding site, which
according to our yeast two-hybrid screen resides in the SH2
domain (Figure 1A). SH2 domains that bind phosphotyrosine
(pY) motifs include a conserved arginine residue corresponding
to arginine-175 in v-Src (Huang et al., 2008). Homologymodeling
of TNS4 SH2 domain superimposed on the v-Src SH2 domain,
identified arginine-474 as a potential putative MET pY binding
site (Figure 2D). Consistent with this prediction, substitution of
arginine-474 with alanine (R474A), in the context of full-length
TNS4-GFP, significantly decreased the MET-TNS4 association
in cells coexpressing MET (Figure 2E). Thus, the association be-
tween phosphorylated MET and TNS4 depends on R474 in the
SH2 domain of TNS4.
The TNS4 SH2 Domain Is Required for Binding MET on
Y1313 and the Docking Site
MET recruits binding partners via key pY residues within its cyto-
plasmic domain (Figure 2F). To test whether the TNS4 SH2
domain directly interacts with MET, and to map the MET pY
residue(s) required for TNS4 association (Figure S2D), we em-
ployed an in vitro ELISA binding assay (Garcia-Echeverria
et al., 1997). Biotinylated MET phosphopeptides encompassing
the juxtamembrane Y1003, the kinase domain Y1234-Y1235 (in
combination), Y1313, the docking-site Y1349 and Y1356 (sepa-
rately or in combination in one peptide), and Y1365 were tested
for their ability to interact with recombinant GST-TNS4-SH2-
PTB. MET peptides containing Y1003 and Y1365 demonstrated
only residual binding to GST-TNS4-SH2-PTB. MET peptides en-
compassing Y1234-Y1235 and Y1349 exhibited intermediate
binding, whereas peptides containing Y1313, Y1356, and the
combination of Y1349 and Y1356 presented the strongest inter-
action with GST-TNS4-SH2-PTB (Figures 2F and 2G). We next
compared a consensus pY recognition sequence reported for
TNS4 SH2 domain binding (Huang et al., 2008) with the MET
phosphopeptide sequences and with a previously reportedrid screen using an intracellular kinase domain-containing fragment of MET. SID
with the respectiveproteinof interest.Functionaldomains in theSIDsareshown.
NS3-GFP or TNS4-GFP.
T or a kinase-dead mutant of MET (KD).
ET and treated with MET kinase inhibitors PHA (PHA665752, 300 nM), SU
to nonbinding immunoglobulin G (IgG) control immunoprecipitation.
ning (antibody directed against intracellular domain) in control and HGF-treated
coefficient between TNS4-GFP and MET staining in cells (mean ± SEM; n = 25
with Student’s t test). Scale bar, 10 mm.
d (30 ng/ml, for 30 min) A549 cells stained for endogenous TNS4, paxillin, and
colocalization. n = 3 independent experiments. Scale bar, 10 mm.
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Figure 2. TNS4 SH2 Domain Interacts with Several Phosphorylated Tyrosines in MET
(A) Schematic representation of recombinant GST fusion constructs containing TNS4 C terminus SH2 and PTB domains.
(B) A549 and GTL-16 cells treated as indicated with HGF (100 ng/ml, 15 min) or PHA (300 nM, 16 hr) and analyzed by western blot.
(C) Pull-down of MET with recombinant GST-TNS4-SH2-PTB from A549 or GTL-16 cell lysates treated as in (B).
(D) Model of TNS4-SH2 domain (blue) superimposed on the published Src SH2 domain crystal structure (yellow) in complex with a phosphotyrosine (pY) peptide
(gray). The critical arginine in the Src SH2 domain required for pY-binding is indicated in green, and the predicted corresponding arginine residue in TNS4 (R474) is
indicated in red.
(E) GFP-TRAP pull-down in HEK293 cells cotransfected with MET and TNS4-GFP or TNS4-GFP_R474A.
(legend continued on next page)
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TNS4 Inhibits MET Endocytosissequence of DLC-1 that also binds TNS4 SH2domain (Liao et al.,
2007). The results of our binding assays, i.e., the interaction
affinity between MET and TNS4, correlated with the degree of
sequence homology between the MET phosphopeptides and
the consensus pY recognition motif reported for TNS4 SH2
domain (Figure 2H).
The TNS4-MET interaction was further validated in the cellular
context. Transiently transfected TNS4-GFP associated with
TRK-MET-WT (chimeric neurotrophin and MET receptor fusion)
but failed to coimmunoprecipitate the TRK-MET mutant (Mut;
bearing Y1313F, Y1349F, Y1356F, and Y1365F substitutions)
(Figure 2I). The observed residual binding of TNS4 to the mutant
receptor may be due to the intact MET kinase domain that is still
present within the mutant construct that exhibited intermediate
binding to TNS4 in our ELISA assays (Figures 2F and 2G). In
correlation with the in vitro binding, phenylalanine substitution
of Y1003 (TRK-MET-Y1003F) did not abolish the ability of
TNS4-GFP to associate with the MET receptor, whereas muta-
tion of Y1313 (TRK-MET-Y1003F,-Y1313F,-Y1365F) markedly
reduced TNS4 binding to MET. Mutagenesis of the docking-
site residues (TRK-MET-Y1349F,-Y1356F) also reduced TNS4
interaction (Figure 2J). Taken together, these data suggest that
TNS4 binds preferentially to MET via the docking site and the
less well-characterized Y1313 residue within MET.
TNS4, MET, and b1-Integrin Form Complexes
As TNS4-MET association requires the TNS4 SH2 domain (Fig-
ure 2), and as TNS4-b1-integrin interaction is known to occur
through TNS4 PTB domain (adjacent to TNS4 SH2) (Calderwood
et al., 2003; Katz et al., 2007), we hypothesized that these three
proteins may form a complex to regulate cellular functions, such
as cell migration. In A549 cells expressing TNS4-GFP, we
observed overlap between TNS4-GFP, MET, and b1-integrin
staining, particularly in adhesion sites (Figure 3A). In addition,
endogenousMET, TNS4, and b1-integrin coimmunoprecipitated
in HGF-stimulated A549 cells (Figure 3B) and recombinant GST-
TNS4-SH2-PTB associated with both MET and b1-integrin
(Figure 3C). The TNS4-b1-integrin complex was not dependent
on growth factor stimulation, consistent with the ability of tensins
to interact with both phosphorylated and nonphosphorylated
b-integrin tails (Legate and Fa¨ssler, 2009). However, as expected
HGF stimulation increased the recruitment of MET to TNS4
(Figure 3C).
As both b1-integrin and MET are strongly implicated in cell
motility, we tested if TNS4 is involved in cell migration. Analysis
of A549 cell migration on cell-derived matrices revealed a
modest effect of TNS4 silencing on the basal migration of nonsti-
mulated cells. However, loss of TNS4 fully abolished the HGF-(F) Schematic representation of key MET tyrosines and respective known interac
with biotinylated MET phosphopeptides (mean absorbance ± SEM; n = 4; statist
with Student’s t test).
(G) Dose-dependent binding of phosphopeptides to GST-TNS4-SH2-PTB (mean a
pY1365 peptide).
(H) pY sequence alignment highlighting consensus binding site with TNS4 SH2
**Because methionine is commonly considered a bulky hydrophobic residue, we
(I) TNS4-GFP (transiently transfected) coimmunoprecipitation from MDCK cells s
Y1349F, Y1356F, Y1365F (Mut).
(J) TNS4-GFP coimmunoprecipitation from HeLa cells transiently overexpressing
Y1313 and Y1365 (Y1003,-13,-65F) or Y1349 and Y1356 (Y1349, 56F) or empt
Deveinduced cell motility as compared to control HGF-treated cells
(Figure 3D; control small interfering RNA [siRNA] cells in Movie
S1 and TNS4 siRNA cells in Movie S2). Importantly, reintroduc-
tion of an siRNA-resistant TNS4-GFP, and not GFP alone (see
Figure 4B for siRNA D efficiency), restored cell migration compa-
rable to levels seen in control cells. Moreover, expression of
TNS4-GFP alone was sufficient to increase cell migration in con-
trol siRNA-transfected cells (Figure 3E). Importantly, the ability of
TNS4 to interact with MET was critical for cell migration as
expression of the TNS4 MET-binding mutant (TNS4_R474A-
GFP) significantly inhibited basal and more notably HGF-stimu-
lated A549 cell migration (Figure 3F).
TNS4 Positively Regulates MET Levels and Downstream
Signaling
Unexpectedly, we observed that MET and b1-integrin total pro-
tein levels were reduced upon TNS4 silencing (Figure 4A; TNS4
smartpool siRNA [four oligos] and a single independent 30 UTR
RNAi oligo), without significant reduction in the corresponding
transcription levels (quantitative real-time PCR measurements;
mean Rq values ± SD fold changes: 1.04 ± SD 0.33 and
1.03 ± 0.45, respectively, for b1 and MET in TNS4- versus con-
trol-silenced cells, n = 2), indicative of protein level regulation.
TNS4 silencing reduced total b1-integrin levels by 26%–55%
(Figure 4A) and cell-surface b1-integrin expression (Figure S3A).
In contrast, b1-integrin silencing did not influence TNS4 expres-
sion (Figure S3B). Furthermore, this effect was specific to TNS4
as TNS3 downregulation did not markedly affect MET or b1-in-
tegrin levels (Figure S3B). The effect of TNS4 silencing on MET
expression was even more pronounced. TNS4 smartpool siRNA
(four oligos) or a single RNAi oligo (siD) (resulting in a 40%–52%
and 41% reduction in TNS4 expression, respectively) led to a
significant downregulation of MET protein expression (28%
and 59%, respectively as compared to control cells) (Figure 4B).
As expected, TNS4 silencing significantly reduced MET cell-
surface expression (Figure 4C) and influenced MET downstream
signaling. In correlation with decreased MET levels, ligand-
induced MET activation (pMET levels, 30 min HGF) was
impaired together with a 54% reduction in Akt activation
compared to HGF-stimulated control cells (Figure 4D). TNS4-
silencing reduced Akt activation also after 1 or 2 hr HGF
stimulation (Figure S3C). Interestingly, HGF induced a modest
activation of ERK with no significant difference in ERK activity
between control and TNS4 siRNA cells (Figure S3C). Hence,
these data demonstrate a requirement for TNS4 in the mainte-
nance of b1-integrin and MET protein levels and HGF-induced
signaling. However, the ability of TNS4 to support expression
of both receptors is unlikely to be related to the formation oftors. Right panel depicts in vitro ELISA binding assay of GST-TNS4-SH2-PTB
ical significance in comparison with nonbinding pY1365 peptide was analyzed
bsorbance ± SEM; n = 3; statistical significance in comparisonwith nonbinding
domain (Huang et al., 2008). (*For the full peptide sequence, see Table S1.
regarded it as matching with the consensus.)
tably overexpressing TRK-MET-WT or mutated construct TRK-MET-Y1313F,
TNS4-GFP and TRK-MET constructs mutated on Y1003 (Y1003F) or Y1003,
y control construct. *p < 0.05, **p < 0.005, ***p < 0.001.
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Figure 3. TNS4, MET, and b1-Integrin Form
Complexes Influencing A549 Cell Migration
(A) Active b1-integrin (9EG7) and MET (antibody
directed against intracellular domain) staining of
A549 cells overexpressing TNS4-GFP, plated on
fibronectin, and treated with HGF (30 ng/ml,
30 min). Insets highlight areas of overlap between
the three channels. Shown are inverted single
channel images and a merged representative of
three independent experiments. Scale bar, 10 mm.
(B) Coimmunoprecipitation of MET, TNS4, and
b1-integrin from cells treated with HGF (10 ng/ml,
16 hr).
(C) Pull-down of MET and b1-integrin with GST-
TNS4-SH2-PTB from whole-cell lysates ± HGF
(100 ng/ml, 15 min).
(D) Migration of control- or TNS4-silenced
(100 nM, smart pool [SP] of four oligos) A549
cells ± HGF (10 ng/ml), on cell-derived matrices
(mean speed ± SEM of 190 cells tracked for 12 hr;
n = 3). Cell lysates were analyzed for TNS4
silencing efficiency, and tubulin was used as
loading control.
(E) Migration of control- or TNS4-silenced (100 nM,
single RNAi oligo D; described in Figure 4B) A549
cells expressing GFP or TNS4-GFP resistant to
RNAi oligo D on cell-derived matrices (mean
speed ± SEM of 150 cells tracked for 12 hr; n = 3).
(F) Migration of A549 cells overexpressing
GFP, TNS4-GFP_WT, or TNS4-GFP_R474A con-
structs, ± HGF (10 ng/ml), on cell-derived matrices
(mean speed ± SEM of at least 70 cells tracked for
12 hr; n = 3).
Statistical significance was analyzed by Student’s
t test. ***p < 0.0001 (D–F).
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TNS4 Inhibits MET Endocytosisthe MET-b1-integrin-TNS4 complex as b1-integrin silencing had
no effect on MET levels (Figure S3B). Careful observation of the
data also revealed a possible feedback loop between MET
and TNS4 expression. HGF stimulation significantly increased
TNS4 levels (approximately 40%) (Figure S3C), with a modest
increase already detectable after 30 min (Figure 4D and S3D).
Correspondingly, in MET overexpressing GTL-16 cells pharma-
cological inhibition of MET activity reduced endogenous TNS4426 Developmental Cell 29, 421–436, May 27, 2014 ª2014 Elsevier Inc.levels by 64% (Figure S3D), suggesting
a reciprocal positive regulatory loop be-
tween MET and TNS4.
TNS4 Regulates MET Stability
Ligand-induced activation of MET and
subsequent MET receptor internalization,
degradation, and/or recycling is well
established (Parachoniak et al., 2011).
Recent studies have demonstrated that
under basal, non-HGF-induced condi-
tions, several mechanisms may regulate
the half-life of the MET receptor indepen-
dently of ligand binding (Lefebvre et al.,
2012). We investigated whether TNS4
could contribute to the steady-state turn-
over of MET in cells. MET levels remained
nearly unaltered in TNS4_WT-GFP-ex-pressing cells treated with cycloheximide but were clearly
reduced in GFP cells (Figure 4E). A similar pattern was detected
in total MET levels analyzed by western blot (Figure S4A). The
ability of TNS4 to stabilize MET was dependent on the TNS4-
MET interaction as expression of the MET-binding-defective
mutant, TNS4_R474A-GFP, significantly increased MET turn-
over compared to TNS4_WT-GFP (Figure 4F). In addition, the
C terminus of TNS4 was sufficient for MET stabilization as
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TNS4 Inhibits MET Endocytosisreintroduction of TNS4-SH2-PTB lacking the RNAi B target
sequence was able to rescue cell-surface MET levels in TNS4-
silenced cells (Figure 4G).
The difference in protein stability suggested a possible role in
receptor trafficking, as ligand-activated MET is predominantly
degraded following internalization. Using the well-established
cell-surface biotinylation-based endocytosis assay (Mai et al.,
2011; Roberts et al., 2001), we observed that in A549 cells,
MET was constantly endocytosed, even in the absence of HGF
(Figure 4H), most likely due to the low-level basal phosphoryla-
tion of MET present in these cells (Figure 2B). Silencing of
TNS4 clearly increased MET endocytosis but had no significant
effect on basal recycling of endocytosed MET (Figures 4H, S4B,
and S4C; note that twice as much input lysate was used for
siTNS4 cells to achieve comparable levels of MET immunopre-
cipitation). This was validated further by the finding that in cells
overexpressing TNS4, the basal and HGF-induced endocytosis
of MET was slower compared to control GFP cells (Figure 5A).
The role of TNS4 in regulating MET internalization was validated
further with another endocytosis assay employing antibody
labeling and fluorescence-activated cell sorting (FACS) analysis.
The data show that TNS4_WT-GFP expression significantly
reduced the loss of cell-surface MET compared to GFP
cells. Conversely, expression of the MET-binding mutant,
TNS4_R474A-GFP, functioned in a dominant-negative fashion
(similar to TNS4 siRNA) to augment MET uptake from the cell
membrane (Figure 5B). Thus, TNS4 binding to MET functions
to reduce MET endocytosis and retain MET on the membrane,
both under basal, low MET activity and HGF-stimulated condi-
tions. Recently, GGA3 was shown to be critical for MET stability
by regulating MET recycling to the plasma membrane upon HGF
stimulation (Parachoniak et al., 2011). In line with these data, we
find that GGA3 silencing has no effect on MET levels under basal
conditions but significantly increases HGF-induced MET down-
regulation. In contrast, TNS4 silencing reduces MET levels, both
in control andHGF-stimulated cells (Figures 5C and S4D), further
confirming that TNS4 regulates MET traffic at the level of endo-
cytosis and that receptor recycling is regulated by GGA3 as
shown previously (Parachoniak et al., 2011).
We also observed a modest reduction in integrin endocytosis
in TNS4_WT-GFP-expressing cells under basal conditions (Fig-
ure 5D). This could be linked to the obvious cotrafficking of
cell-surface-derived active b1-integrin and MET that was
observed upon HGF induction (Figure 5E).
TNS4 Inhibits MET Trafficking toward a Lysosomal
Compartment
Next, we examined the localization of MET in the presence of
TNS4_WT-GFP or the binding-incompetent TNS4_R474A-GFP
mutant, both transiently expressed with lysosomal marker
Lamp1-RFP (Figures 5F and S5A). We observed faster MET traf-
ficking toward the lysosomal compartment in TNS4_R474A
mutant-expressing cells compared to TNS4_WT cells, especially
following 10 min of ligand stimulation. In line with this,
after 30 min, very little MET remained detectable in the
TNS4_R474A-expressing cells compared to the much higher
MET signal residing in the Lamp-1 vesicles of TNS4_WT cells
(Figure S5A). The loss in intracellular MET staining upon TNS4
silencing was rescued with bafilomycin, a lysosomal inhibitorDeve(Figure S5B). Interestingly, in control-silenced cells, with lower
basal MET endocytosis, bafilomycin clearly increased focal
adhesion-type localization of MET at the plasma membrane.
However, this phenomenon remains to be investigated in future
studies. Taken together, the presence of functional TNS4 pro-
tects MET from degradation under basal conditions and affects
MET lysosomal targeting upon HGF stimulation.
TNS4 and MET Expressions Correlate in Colorectal and
Ovarian Tumors
Human colorectal and ovarian cancers exhibit typically highMET
expression (Birchmeier et al., 2003; Zhou et al., 2008). In addi-
tion, TNS4 has been identified as an oncogene in colorectal can-
cer (Albasri et al., 2009; Liao et al., 2009). Our data indicate that
TNS4 levels correlate with MET protein stability in cell lines. To
investigate whether this is applicable in vivo, we stained for
TNS4 and MET in human tumor specimens. From a large cohort
(A˚lgars et al., 2011) of metastatic or locally advanced colorectal
cancers, ten were selected because of their strong MET immu-
noreactivity in invasive areas and heterogeneous overall staining
in the tumor. Independent scoring of staining intensity, in 80
areas of serial histology sections, demonstrated a significant
correlation between MET and TNS4 staining within the same
regions of the tumor (p < 0.0001) (Figure 6A).
Next, an ovarian tumor tissuemicroarray containing 196 tumor
cores was stained for MET and TNS4 (Figure 6B). Whereas all
tumor cores were immunoreactive for TNS4, 17 cases showed
no staining for MET. TNS4 showed weak expression in 32 cases,
moderate expression in 99 cases, and intense expression in 65
cases. MET staining was weak in 54 cases, moderate in 61
cases, and intense in 64 cases. The level of TNS4 and MET
immunoreactivity correlated significantly (p < 0.0001) when all
tumor cores were studied from adjacent histology slices from
the same samples (Figure 6B). After exclusion of benign and
borderline tumors from the analysis, the correlation remained
significant (p < 0.0001). However, differences between histolog-
ical subtypes of carcinomas were observed. In high-grade
serous carcinomas (n = 49; p < 0.0001) and in mucinous carci-
noma (n = 39; p = 0.012), TNS4 and MET staining correlated
significantly. In endometrioid cystadenocarcinoma (n = 43; p =
0.13) such a correlation was not seen, suggesting that in some
tumor types the regulatory activity of TNS4 on MET expression
may be overcome by alternative pathways. Taken together,
these data implicate TNS4 as a potential regulator of MET levels
in human cancer.
TNS4 Is Required for MET-Induced Survival In Vitro and
In Vivo
Both HGF/MET signaling and integrin-mediated cell adhesion
regulate cell proliferation. By using the IncuCyte-automated
incubator-microscope system (Haapa-Paananen et al., 2012),
we observed a clear reduction in cell proliferation following
TNS4 silencing (Figures 7A and S6A), correlating with reduced
MET and b1-integrin levels in TNS4-silenced cells. However,
the antiproliferative effect of TNS4 silencing is most likely linked
to MET downregulation. Indeed, MET silencing abolished cell
proliferation, whereas silencing of b1-integrin had no significant
effect (Figures S6A and S6B). The effect of TNS4 silencing on
cell proliferation (Figure 7B) was rescued with the concomitantlopmental Cell 29, 421–436, May 27, 2014 ª2014 Elsevier Inc. 427
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TNS4 Inhibits MET Endocytosisexpression of a construct containing only TNS4 SH2-PTB and
lacking the RNAi B target sequence, demonstrating the speci-
ficity of TNS4 silencing on cell proliferation.
In a subset of cancers,MET is amplified, resulting in increased
proliferation and dependence of cells on MET signaling in the
form of oncogene addiction (Lutterbach et al., 2007). We inves-
tigated the effect of TNS4 silencing in three carcinoma cell lines
with MET amplification (resulting in constitutively active MET)
and in another cell line with lower levels of MET (and no basal
MET activity): MET-addicted EBC-1 lung carcinoma, MKN-45
and GTL-16 gastric carcinoma cells, and nonaddicted OVCAR3
ovarian carcinoma cell line (Figure S6C). All of these cell lines ex-
pressed TNS4 (Figures 7C, 7D, and S6D), and similar to A549
cells, TNS4-silencing resulted in MET downregulation and a sig-
nificant reduction in proliferation in the active MET-expressing
cells (Figures 7D and S6D). However, in OVCAR3 cells, TNS4
silencing significantly affectedMET downregulation and cell pro-
liferation only in the presence of constant HGF stimulation (Fig-
ure 7C). These data demonstrate a MET-activity dependence
for TNS4 in regulating MET-induced cell growth in different cell
lines representing several cancer types. In cell lines with MET
amplification (Lutterbach et al., 2007), including GTL-16 (Smolen
et al., 2006), MET downregulation halts proliferation, ultimately
resulting in apoptosis. Accordingly, we detected increased
apoptosis in GTL-16 and MKN-45 cells upon suppression of
TNS4 expression (Figures 7E and S6E).
To experimentally validate these data in vivo, control- and
TNS4-silenced GTL-16 cells were grafted subcutaneously into
nude mice to generate tumors in vivo (Bertotti et al., 2010).
Consistent with the observed MET dependence of GTL-16 cells
in vitro, tumors derived from TNS4-silenced GTL-16 cells were
predominantly necrotic with only marginal areas of viable cells.
This was in stark contrast to the control RNAi GTL-16 tumors
in which the majority of the cells were viable (Figure 7F). Residual
Ki67 and excessive terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) staining in TNS4-silenced tumor
sections confirmed reduced viability compared to the control-
silenced tumors (Figure 7G). Immunohistochemistry staining
further revealed that the remaining small areas of viable cells in
the TNS4 RNAi-treated tumors were in fact positive for TNS4,
MET, and pMET (Figure S6F), suggesting that these viable tumor
areas may have arisen from the subpopulation of nontargeted
cells that are always present in RNAi-silenced cell populations.Figure 4. TNS4 Regulates MET Stability
(A) A549 cells transfected with control or TNS4 siRNAs (100 nMSP or a single RNA
normalized to tubulin and relative to control-silenced cells; n = 3 independent ex
(B) Representative western blot showing TNS4 and MET reduction (analyzed as
(C) FACS analysis of MET cell surface levels in A549 cells treated with control or T
to control-silenced cells; n = 3). Lower panel shows representative FACS histogr
(D) Western blot analysis of MET, pMET, pAkt, and Akt levels in control- or TNS
(50 ng/ml, 30 min) (mean ± SEM band intensity normalized to tubulin and relative
(E) FACS analysis of MET cell-surface levels in A549-TNS4_WT-GFP and control
Shown are representative histograms and quantifications (mean values ± SEM n
(F) Cell-surface MET levels compared in A549-TNS4_R474A-GFP and A549-TNS
(G) FACS analysis ofMET cell surface levels in control- or TNS4 (siB)-silenced A549
were allowed to endocytose MET for 30 min (mean ± SEM fluorescence intensit
(H) Endocytosis rate of biotinylated cell-surface MET in control- and TNS4 (SP)-s
SEM band intensity normalized to end point [10 min]), relative to control-silenced
Statistical significance was analyzed by Student’s t test. *p < 0.05, **p < 0.005, *
DeveThese data demonstrate that TNS4 is necessary for MET-depen-
dent cancer cell proliferation and survival in vitro and in vivo.
DISCUSSION
The MET interactome has been studied extensively in recent
years and many proteins facilitating MET downstream signaling
have been identified (Gherardi et al., 2012). In this study, we pro-
vide evidence for a previously unidentified direct interaction
betweenMET and TNS4.We further dissect how TNS4 regulates
the stability of MET at the protein level, thus promoting MET
prosurvival activity both in vitro and in vivo (summarized in
Figure 7H).
Although many of the details of HGF-induced MET trafficking
are well known (Hammond et al., 2001; Peschard et al., 2001),
the precise mechanisms regulating turnover of this receptor in
human carcinomas remain unidentified. We find that MET pro-
tein stability is critically regulated by the ability of the receptor
to couple to the intracellular scaffold protein TNS4, recently
described as an oncogene in multiple cancer types. TNS4 ex-
pression inhibits MET endocytosis and correlates with increased
MET levels and protein stability. Conversely, introduction of a
defective MET-binding TNS4 mutant or TNS4 silencing in-
creases MET endocytosis, lysosomal targeting, and degrada-
tion, thus significantly reducing MET levels. Consistent with
these in vitro data, examination of human colonic and ovarian
tumors, where MET overexpression has been correlated with
poor outcome (reviewed in Blumenschein et al., 2012), revealed
a high degree of conformity between MET and TNS4 immunore-
activity, suggesting coregulation of MET and TNS4 in vivo.
A previous study described a critical role for the intact TNS4
SH2 domain in the developmental process of HGF-induced
tubulogenesis. However, the critical molecular interactions
mediated by the TNS4 SH2 domain were not investigated in
detail in that study (Kwon et al., 2011). Interestingly, we demon-
strate that TNS4 interacts with several phosphorylated tyrosines
on MET, namely, Y1349 and Y1356, which form the multifunc-
tional docking site (Trusolino et al., 2010) and with the less
well-characterized Y1313. As TNS4 plays a fundamental role in
MET stabilization, the existence of multiple TNS4 binding sites
is not surprising and would potentially allow TNS4 binding
even if Y1313 or the docking site are monopolized by other
MET-binding downstream effectors.i oligo in 30 UTR end) and analyzed by western blot (mean ± SEMband intensity
periments).
in A) in A549 cells following TNS4 silencing with SP or RNAi oligo D.
NS4 SP RNAi or TNS4 RNAi D (mean fluorescence intensities ± SD, normalized
ams.
4-silenced (SP) A549 cells treated with DMSO (control) or HGF as indicated
to control-silenced DMSO-treated cells; n = 3).
A549-GFP cells treated with cycloheximide (10 mg/ml) for the indicated times.
ormalized to 0 hr time points; n = 3).
4_WT-GFP cells as described in (E).
cells expressing GFP or GFP-TNS4-SH2-PTB fragment (resistant to siB). Cells
y; n = 3).
ilenced A549 cells ± HGF (30 ng/ml). Representative blots are shown (mean ±
cells. Lysate input in TNS4 (SP) cells equivalent to 200% of control input (n = 3).
**p < 0.0005 (A–G).
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gene expression, frequently detected in cancer (Zou et al.,
2007), MET protein levels are controlled by TNS4. Hence, the
ability of TNS4 to stabilize MET delineates an additional impor-
tant level of MET regulation. Interestingly, we find a positive
feedback loop between MET signaling and TNS4 through which
HGF stimulation increases TNS4 levels and MET inhibition has
the opposite effect. These data support the role of HGF in
inducing TNS4 in MDCK cells (Kwon et al., 2011). We further
observed that TNS4 levels are linked to increased b1-integrin
stability and there are several cancer types, including breast
cancer, in which elevated integrin expression is linked to poor
prognosis (Goodman and Picard, 2012). The ability of TNS4 to
regulate the endocytosis of and to stabilize MET and integrins
is most likely one of the mechanisms whereby TNS4 mediates
oncogenicity.
TNS4 was very recently implicated in stabilization of EGFR
following EGF stimulation (Hong et al., 2013) and is transcription-
ally regulated by EGFR signaling in mammary epithelial cells
(Katz et al., 2007) and by BRAF in KRAS-mutated colorectal can-
cers (Al-Ghamdi et al., 2011). These data suggest that TNS4
could function not only as a regulator of several RTKs but also
as an important node linking distinct oncogenic pathways in can-
cer cells. Here, we describe TNS4 as an important regulator of
MET protein stability and MET-dependent cell survival. It is
also possible that TNS4 couples EGFR or BRAF signaling to
MET stability; however, this remains to be investigated.
In conclusion, our study demonstrates a direct interaction be-
tweenMET and TNS4 that influencesMET stability and regulates
survival of MET-dependent carcinomas in vitro and in vivo. TNS4
supports prolonged MET plasma membrane localization, thus
sustaining MET oncogenic signaling, and the significant coex-
pression of MET and TNS4 in ovarian and colon carcinomas sug-
gests that this interaction is of putative clinical importance.
EXPERIMENTAL PROCEDURES
Cell Lines and DNA Constructs
For cell lines, culture conditions, and DNA constructs, see the Supplemental
Experimental Procedures.
Antibodies and Reagents
Antibodies, RNAi oligomers, and phosphopeptides used are listed in the
Supplemental Experimental Procedures. HGF, NGF, and cycloheximide
were purchased from Sigma. PHA665752, SU1174, and bovine plasma fibro-
nectin were purchased from Calbiochem, and INCB28060 was purchased
from Selleckchem.Figure 5. TNS4-MET Interaction Attenuates MET Internalization and Ly
(A) Endocytosis rate of biotinylated cell-surface MET in A549-TNS4_WT-GFP
normalized to end point [20 min]; n = 3). Statistical differences at each time poi
Student’s t test.
(B) FACS analysis of cell-surface MET endocytosis rate in A549-GFP, A549-TNS4
SEM fluorescence intensity; n = 3).
(C) Total MET levels in control-, TNS4-, and GGA3-silenced A549 cells treated w
control-silenced cells; n = 3). Statistical significance was analyzed between cont
(D) Endocytosis rate of biotinylated cell-surface b1-integrin was measured as de
(E) MET and active b1-integrin coendocytosis upon HGF induction (30 ng/ml) i
extracellular domain) and b1-integrin (12G10) antibodies. Scale bar, 10 mm.
(F) A549 cells cotransfected with TNS4 _WT-GFP or TNS4_R474A-GFP mutant a
domain) after HGF (30 ng/ml) induction. r: Pearson’s correlation coefficient betwee
Scale bar, 10 mm. *p < 0.05, **p < 0.005, ***p < 0.0005.
DeveYeast Two-Hybrid
The yeast two-hybrid screen was performed by Hybrigenics using humanMET
(amino acids 1003–1376) as bait on a human placenta cDNA library.
DNA and RNAi Transfections
DNA construct and siRNA transfections were carried out using Lipofectamine
2000 (Life Technologies) or HiPerFect (QIAGEN) according to the manufac-
turer’s instructions.
Immunoprecipitation and Western Blotting
See Supplemental Experimental Procedures.
Phosphopeptide Binding Assay
The in vitro ELISA binding assay was adapted from Garcia-Echeverria et al.
(1997). For further details and for modeling of TNS4 SH2 domain binding to
phosphotyrosine peptide, see the Supplemental Experimental Procedures.
Microscopy and Image Analysis
See the Supplemental Experimental Procedures.
FACS Analysis
Cells were detached with HyQ Tase (HyClone) and fixed with PBS containing
2% PFA for 15 min at room temperature. Cell-surface MET was stained with
MET-extracellular antibody (1/100 from R&D) for 1 hr at 4C. After washing
once with PBS, Alexa Fluor-conjugated secondary antibody was added and
incubated for 1 hr at 4C. Samples were analyzed with FACS array (Becton
Dickinson). The mean fluorescent intensity was determined from 10,000 or
20,000 counted events. For the FACS-based endocytosis assay, adherent
cells were labeled with nonstimulating extracellular domain-binding MET anti-
body (1:500, Ebioscience) on ice for 30 min. Unbound antibody was washed
away, and the cells were chased in warm medium in the presence or absence
of 30 ng/ml HGF. Cells were washed with cold PBS and carefully collected by
scraping. Cells were fixed for 10 min at 4C with 4% PFA, washed, and sus-
pended in PBS followed by Alexa-647 conjugated secondary antibody staining
and FACS analysis.
Biotin IP-Based Internalization and Recycling Assay
MET and b1-integrin endocytosis and MET recycling rates were measured
using a cell-surface biotinylation-based assay as previously described (Arjo-
nen et al., 2012). Briefly, cells were grown to 80% confluence, placed on ice,
and washed once with cold PBS, and cell-surface proteins were labeled
with 0.5 mg/ml of EZ-link cleavable sulfo-NHS-SS-biotin (#21331; Thermo
Scientific) in Hanks’ balanced salt solution (H9269; Sigma) for 30 min at 4C.
Unbound biotin was removed, and cells were washed with cold media and
allowed to internalize receptors in prewarmed 10% serum-containing medium
at 37C for the indicated times. Cells were then quickly placed back on ice with
the addition of cold media. The remaining biotin at the cell surface was
removed with 60 mM MesNa (63705; sodium 2-mercaptoethanesulfonate:
Fluka) in MesNa buffer (50 mM Tris-HCl [pH 8.6], 100 mM NaCl) for 30 min
at 4C, followed by quenching with 100 mM iodoacetamide (IAA, Sigma) for
15 min on ice. To detect the total surface biotinylation, one of the cell dishes
was left on ice after biotin labeling and did not undergo internalization orsosomal Targeting
and control A549-GFP cells ± HGF (30 ng/ml) (mean ± SEM band intensity
nt between GFP- and TNS4_WT-GFP-overexpressing cells were analyzed by
_WT-GFP, or A549-TNS4_R474A-GFP cells ± HGF (30 ng/ml, 30 min) (mean ±
ith DMSO or HGF (30 ng/ml, 1 hr) (mean ± SEM band intensity normalized to
rol-silenced cells and the other conditions.
scribed in (A).
n A549 cells labeled with cell-surface-bound MET (antibody directed against
nd Lamp1-RFP were stained for MET (antibody directed against extracellular
n Lamp1-RFP andMET staining in cells (mean ± SEM; n = 7 cells per condition).
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Figure 6. TNS4 and MET Are Coexpressed in the Same Areas of Colorectal and Ovarian Epithelial Tumors
(A) MET and TNS4 staining of adjacent colorectal cancer sections from the same tumor (magnification 320).
(B) MET and TNS4 staining of adjacent sections of ovarian tumor tissue microarray spots (magnification 310). ***p < 0.0001.
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TNS4 Inhibits MET EndocytosisMesNa treatment. Cells were then washed with PBS, scraped in lysis buffer
(1.5% octylglucoside, 1% NP-40, 0.5% BSA, 1 mM EDTA with phosphatase
and protease inhibitor cocktail tablets [Roche]) at 4C for 20 min. In recycling
experiments, following the first MesNA/IAA treatment, the cells were returned432 Developmental Cell 29, 421–436, May 27, 2014 ª2014 Elsevier Into prewarmed 10% serum-containing medium at 37C for the indicated times
and treated again with MesNa/IAA to remove biotin from the cell-surface re-
cycled receptor. All cell extracts were cleared by centrifugation (14,000 3 g,
10 min, 4C), and biotinylated MET or integrin were immunoprecipitatedc.
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beads (17-0618-01; GE Healthcare).
Biotinylated internalized MET and b1-integrin receptors and total receptor
levels were detected by immunoblotting with horseradish peroxidase (HRP)-
conjugated anti-biotin antibody (#7075; Cell Signaling Technology) and recep-
tor-specific antibodies, respectively.
Enhanced chemiluminescence-detected biotin and receptor signals were
quantified as integrated densities of protein bands with ImageJ (v. 1.43u),
and each biotin signal was normalized to the corresponding receptor and total
biotin signal. The endocytosis rate of MET was similarly measured in control-
or TNS4-silenced cells.
Animal Studies
Experimental procedures were approved by the Committee for Care and
Use of Animals in Experiments at the University of Turku and the State
Provincial office of Western Finland (authorization ESLM-2008-08600).
TNS4- or control-silenced GTL-16 cells (2.106) were subcutaneously injected
in one flank of ten athymic nude mice (5–6 weeks old females, Harlan) for
each cell type. Mice were sacrificed 12 days after injection. Tumors were
removed and fixed in formalin before paraffin inclusion. All tumor sections
were stained for hematoxylin and eosin to quantify viable tumoral tissue. For
Ki67 and TUNEL staining, tumor sections from three mice in each group
were compared.
Immunohistochemical Staining of Human Tumor Samples
Tumor sections were formalin fixed, paraffin embedded, and stained with
antibodies against TNS4 and MET using Ventana BenchMark XT (Ventana
Medical Systems, Roche Diagnostics). See the Supplemental Experimental
Procedures for detailed staining and scoring protocols.
In Vitro Proliferation and Survival Assay
Cells were imaged in an IncuCyteHD (Essen Instruments) automated incubator
microscope, and cell confluence was calculated per well by associated soft-
ware algorithm (Haapa-Paananen et al., 2012). WST-1 in vitro proliferation
assay (Roche) was used to measure A549 and OVCAR3 cells proliferation.
Apoptosis was measured using DEVD 488 Nucview substrate (1 mM, Essen
BioScience) of caspase-3/7. For further details, see the Supplemental Exper-
imental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, one table, and two movies and can be found with this article online
at http://dx.doi.org/10.1016/j.devcel.2014.03.024.Figure 7. TNS4 Silencing Induces MET Downregulation Associated wit
(A) Proliferation of control- or TNS4-silenced (SP) A549 cells analyzed by IncuCyt
n = 5). Corresponding cell lysates were analyzed by western blot.
(B) Proliferation of A549 cells transfected with either control or TNS4 siRNAs (SP o
IncuCyteHD incubator microscope (mean confluence values were compared at
silenced cell extracts; lane 2: TNS4 SP; lane 3: TNS4 RNAi B).
(C) WST-1 proliferation assay of control- or TNS4 (SP)-silenced OVCAR3 cells ±
Statistical significancewas analyzed at each time point between untreated control
HGF-treated TNS4-silenced cells at the indicated time point (*p < 0.05). Corresp
(D) Proliferation of control- or TNS4-silencedGTL-16 cells analyzed with IncuCyteH
lysates were analyzed by western blot.
(E) Apoptosis of control- or TNS4-silenced GTL-16 and MKN-45 cells detected
microscope. Shown are fluorescent apoptotic cell counts (normalized to cell con
(F) Quantification of tumor viability in xenograft sections of transplanted GTL-16 c
(magnification 310). *p < 0.05, **p < 0.005,***p < 0.0001.
(G) Ki67, TUNEL, and IgG (negative control) staining of tumor sections used in (F
(H) Proposed model: TNS4 interacts with b1-integrin and MET to inhibit internali
MET expression correlates with sustained MET signaling and increased cancer
panel) results in increasedMET internalization and either subsequent MET recyclin
et al., 2011) via the previously described GGA3 pathway or leads to increased ly
signaling.
434 Developmental Cell 29, 421–436, May 27, 2014 ª2014 Elsevier InAUTHOR CONTRIBUTIONS
G.M. designed and performed experiments, analyzed data, and wrote the
paper; P.S. and T.K. contributed equally; P.S. performed and analyzed the
trafficking experiments, and T.K. performed and analyzed the histology
staining. N.D.F. performed the sequence analysis and structural modeling.
R.K. assisted with the cell-derived matrix experiments. K.C. and D.T. provided
research tools, expertise, and help with the protein-interaction studies. The
yeast two-hybrid experiments were carried out in D.T.’s laboratory. O.C. de-
signed the experiments related to the clinical material, analyzed data, and
contributed to writing the paper. J.I. designed and performed experiments,
discussed data, and wrote the paper.
ACKNOWLEDGMENTS
The authors are very grateful for technical assistance from J. Nevo, E. Mattila,
L. Lahtinen, J. Siivonen, and P. Laasola. Dr. H. Hamidi is acknowledged for sci-
entific writing, and Professor J. Westermarck is acknowledged for critically
reading the manuscript. Professor D. Critchley (University of Leicester) is
acknowledged for support in generating Tensin constructs and TNS3 anti-
body. Dr. G. Serini (University of Torino) is acknowledged for providing
Lamp1-RFP construct. K.C. has been funded by the Wellcome Trust. P.S. is
funded by the Turku Doctoral program of Molecular Medicine (TuDMM). This
study has been supported by the Academy of Finland, an ERC Starting Grant,
an ERC Consolidator Grant, the Sigrid Juselius Foundation, and the Finnish
Cancer Organizations.
Received: June 7, 2013
Revised: February 5, 2014
Accepted: March 31, 2014
Published: May 8, 2014
REFERENCES
Al-Ghamdi, S., Albasri, A., Cachat, J., Ibrahem, S., Muhammad, B.A., Jackson,
D., Nateri, A.S., Kindle, K.B., and Ilyas, M. (2011). Cten is targeted by Kras
signalling to regulate cell motility in the colon and pancreas. PLoS ONE 6,
e20919.
Albasri, A., Seth, R., Jackson, D., Benhasouna, A., Crook, S., Nateri, A.S.,
Chapman, R., and Ilyas, M. (2009). C-terminal Tensin-like (CTEN) is an onco-
gene which alters cell motility possibly through repression of E-cadherin in
colorectal cancer. J. Pathol. 218, 57–65.
A˚lgars, A., Lintunen, M., Carpe´n, O., Ristama¨ki, R., and Sundstro¨m, J. (2011).
EGFR gene copy number assessment from areas with highest EGFRh Reduced Cell Proliferation and Survival In Vitro and In Vivo
eHD incubator microscope (mean confluence values were compared at 70 hr;
r single TNS4 RNAi B) ± TNS4-SH2-PTB-GFP rescue construct as analyzed by
70 hr; n = 3). Western blot shows TNS4 silencing efficiency (lane 1: control-
HGF (5 ng/ml) (mean ± SEM; absorbance normalized to day 1 values; n = 3).
- versus TNS4-silenced cells (nonsignificant) or HGF-stimulated control- versus
onding cell lysates were analyzed by western blot.
D (mean confluence valueswere compared at 70 hr; n = 3). Corresponding cell
using DEVD-488 Nucview Caspase3/7 substrate in IncuCyteFLR incubator
fluence per well; mean ± SEM; n = 2–3).
ells (n = 10 mice per group). Viable cells are outlined in representative images
).
zation and subsequent degradation of both receptors. TNS4-dependent high
cell survival, motility, and proliferation. Suppression of TNS4 expression (right
g back to the cell surface in a HGF-activation-dependent manner (Parachoniak
sosomal degradation associated with decreased MET levels and downstream
c.
Developmental Cell
TNS4 Inhibits MET Endocytosisexpression predicts response to anti-EGFR therapy in colorectal cancer. Br. J.
Cancer 105, 255–262.
Arjonen, A., Alanko, J., Veltel, S., and Ivaska, J. (2012). Distinct recycling of
active and inactive b1 integrins. Traffic 13, 610–625.
Bertotti, A., Bracco, C., Girolami, F., Torti, D., Gastaldi, S., Galimi, F., Medico,
E., Elvin, P., Comoglio, P.M., and Trusolino, L. (2010). Inhibition of Src impairs
the growth of met-addicted gastric tumors. Clin. Cancer Res. 16, 3933–3943.
Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G.F. (2003).
Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4, 915–925.
Blumenschein, G.R., Jr., Mills, G.B., and Gonzalez-Angulo, A.M. (2012).
Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J. Clin.
Oncol. 30, 3287–3296.
Calderwood, D.A., Fujioka, Y., de Pereda, J.M., Garcı´a-Alvarez, B., Nakamoto,
T., Margolis, B., McGlade, C.J., Liddington, R.C., and Ginsberg, M.H. (2003).
Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding
domains: a structural prototype for diversity in integrin signaling. Proc. Natl.
Acad. Sci. USA 100, 2272–2277.
Chen, N.T., Kuwabara, Y., Conley, C., Liao, Y.C., Hong, S.Y., Chen, M., Shih,
Y.P., Chen, H.W., Hsieh, F., and Lo, S.H. (2013). Phylogenetic analysis,
expression patterns, and transcriptional regulation of human CTEN gene.
Gene 520, 90–97.
Clark, K., Howe, J.D., Pullar, C.E., Green, J.A., Artym, V.V., Yamada, K.M., and
Critchley, D.R. (2010). Tensin 2 modulates cell contractility in 3D collagen gels
through the RhoGAP DLC1. J. Cell. Biochem. 109, 808–817.
Cui, Y., Liao, Y.C., and Lo, S.H. (2004). Epidermal growth factor modulates
tyrosine phosphorylation of a novel tensin family member, tensin3. Mol.
Cancer Res. 2, 225–232.
Defilippi, P., Di Stefano, P., and Cabodi, S. (2006). p130Cas: a versatile scaf-
fold in signaling networks. Trends Cell Biol. 16, 257–263.
Garcia-Echeverria, C., Stamm, C., Wille, R., Arz, D., and Gay, B. (1997).
Biotinylated phosphotyrosine containing peptides: a valuable tool for studies
on phosphopeptide interactions with SH2 and PTB domains. Lett. Pept. Sci.
4, 49–53.
Gherardi, E., Birchmeier, W., Birchmeier, C., and Vande Woude, G. (2012).
TargetingMET in cancer: rationale and progress. Nat. Rev. Cancer 12, 89–103.
Goodman, S.L., and Picard, M. (2012). Integrins as therapeutic targets. Trends
Pharmacol. Sci. 33, 405–412.
Haapa-Paananen, S., Kiviluoto, S., Waltari, M., Puputti, M., Mpindi, J.P.,
Kohonen, P., Tynninen, O., Haapasalo, H., Joensuu, H., Pera¨la¨, M., and
Kallioniemi, O. (2012). HES6 gene is selectively overexpressed in glioma and
represents an important transcriptional regulator of glioma proliferation.
Oncogene 31, 1299–1310.
Hammond, D.E., Urbe´, S., Vande Woude, G.F., and Clague, M.J. (2001).
Down-regulation of MET, the receptor for hepatocyte growth factor.
Oncogene 20, 2761–2770.
Hammond, D.E., Carter, S., McCullough, J., Urbe´, S., Vande Woude, G., and
Clague, M.J. (2003). Endosomal dynamics of Met determine signaling output.
Mol. Biol. Cell 14, 1346–1354.
Hong, S.Y., Shih, Y.P., Li, T., Carraway, K.L., 3rd, and Lo, S.H. (2013). CTEN
prolongs signaling by EGFR through reducing its ligand-induced degradation.
Cancer Res. 73, 5266–5276.
Houldsworth, J., Cordon-Cardo, C., Ladanyi, M., Kelsen, D.P., and Chaganti,
R.S. (1990). Gene amplification in gastric and esophageal adenocarcinomas.
Cancer Res. 50, 6417–6422.
Huang, H., Li, L., Wu, C., Schibli, D., Colwill, K., Ma, S., Li, C., Roy, P., Ho, K.,
Songyang, Z., et al. (2008). Defining the specificity space of the human SRC
homology 2 domain. Mol. Cell. Proteomics 7, 768–784.
Ivaska, J., and Heino, J. (2011). Cooperation between integrins and growth
factor receptors in signaling and endocytosis. Annu. Rev. Cell Dev. Biol. 27,
291–320.
Joffre, C., Barrow, R., Me´nard, L., Calleja, V., Hart, I.R., and Kermorgant, S.
(2011). A direct role for Met endocytosis in tumorigenesis. Nat. Cell Biol. 13,
827–837.DeveKatz, M., Amit, I., Citri, A., Shay, T., Carvalho, S., Lavi, S., Milanezi, F., Lyass,
L., Amariglio, N., Jacob-Hirsch, J., et al. (2007). A reciprocal tensin-3-cten
switch mediates EGF-driven mammary cell migration. Nat. Cell Biol. 9,
961–969.
Kermorgant, S., Zicha, D., and Parker, P.J. (2004). PKC controls HGF-depen-
dent c-Met traffic, signalling and cell migration. EMBO J. 23, 3721–3734.
Kwon, S.H., Nedvetsky, P.I., and Mostov, K.E. (2011). Transcriptional profiling
identifies TNS4 function in epithelial tubulogenesis. Curr. Biol. 21, 161–166.
Lai, A.Z., Abella, J.V., and Park, M. (2009). Crosstalk in Met receptor oncogen-
esis. Trends Cell Biol. 19, 542–551.
Lefebvre, J., Ancot, F., Leroy, C., Muharram, G., Lemie`re, A., and Tulasne, D.
(2012). Met degradation: more than one stone to shoot a receptor down.
FASEB J. 26, 1387–1399.
Legate, K.R., and Fa¨ssler, R. (2009). Mechanisms that regulate adaptor bind-
ing to beta-integrin cytoplasmic tails. J. Cell Sci. 122, 187–198.
Liao, Y.C., Si, L., deVere White, R.W., and Lo, S.H. (2007). The phosphotyro-
sine-independent interaction of DLC-1 and the SH2 domain of cten regulates
focal adhesion localization and growth suppression activity of DLC-1. J. Cell
Biol. 176, 43–49.
Liao, Y.C., Chen, N.T., Shih, Y.P., Dong, Y., and Lo, S.H. (2009). Up-regulation
of C-terminal tensin-like molecule promotes the tumorigenicity of colon cancer
through beta-catenin. Cancer Res. 69, 4563–4566.
Lo, S.H. (2007). Reverse interactomics: from peptides to proteins and to func-
tions. ACS Chem. Biol. 2, 93–95.
Lo, S.H., and Lo, T.B. (2002). Cten, a COOH-terminal tensin-like protein with
prostate restricted expression, is down-regulated in prostate cancer. Cancer
Res. 62, 4217–4221.
Lutterbach, B., Zeng, Q., Davis, L.J., Hatch, H., Hang, G., Kohl, N.E., Gibbs,
J.B., and Pan, B.S. (2007). Lung cancer cell lines harboring MET gene ampli-
fication are dependent on Met for growth and survival. Cancer Res. 67,
2081–2088.
Mai, A., Veltel, S., Pellinen, T., Padzik, A., Coffey, E., Marjoma¨ki, V., and Ivaska,
J. (2011). Competitive binding of Rab21 and p120RasGAP to integrins regu-
lates receptor traffic and migration. J. Cell Biol. 194, 291–306.
McCleverty, C.J., Lin, D.C., and Liddington, R.C. (2007). Structure of the PTB
domain of tensin1 and a model for its recruitment to fibrillar adhesions. Protein
Sci. 16, 1223–1229.
Mitra, S.K., and Schlaepfer, D.D. (2006). Integrin-regulated FAK-Src signaling
in normal and cancer cells. Curr. Opin. Cell Biol. 18, 516–523.
Muller, P.A., Trinidad, A.G., Timpson, P., Morton, J.P., Zanivan, S., van den
Berghe, P.V., Nixon, C., Karim, S.A., Caswell, P.T., Noll, J.E., et al. (2013).
Mutant p53 enhances MET trafficking and signalling to drive cell scattering
and invasion. Oncogene 32, 1252–1265.
Parachoniak, C.A., Luo, Y., Abella, J.V., Keen, J.H., and Park, M. (2011). GGA3
functions as a switch to promote Met receptor recycling, essential for sus-
tained ERK and cell migration. Dev. Cell 20, 751–763.
Peschard, P., Fournier, T.M., Lamorte, L., Naujokas, M.A., Band, H., Langdon,
W.Y., and Park, M. (2001). Mutation of the c-Cbl TKB domain binding site on
the Met receptor tyrosine kinase converts it into a transforming protein. Mol.
Cell 8, 995–1004.
Qian, X., Li, G., Vass, W.C., Papageorge, A., Walker, R.C., Asnaghi, L.,
Steinbach, P.J., Tosato, G., Hunter, K., and Lowy, D.R. (2009). The Tensin-3
protein, including its SH2 domain, is phosphorylated by Src and contributes
to tumorigenesis and metastasis. Cancer Cell 16, 246–258.
Roberts, M., Barry, S., Woods, A., van der Sluijs, P., and Norman, J. (2001).
PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early
endosomes is necessary for cell adhesion and spreading. Curr. Biol. 11, 1392–
1402.
Rong, S., Segal, S., Anver, M., Resau, J.H., and Vande Woude, G.F. (1994).
Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte
growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci.
USA 91, 4731–4735.lopmental Cell 29, 421–436, May 27, 2014 ª2014 Elsevier Inc. 435
Developmental Cell
TNS4 Inhibits MET EndocytosisSakashita, K., Mimori, K., Tanaka, F., Kamohara, Y., Inoue, H., Sawada, T.,
Hirakawa, K., and Mori, M. (2008). Prognostic relevance of Tensin4 expression
in human gastric cancer. Ann. Surg. Oncol. 15, 2606–2613.
Sasaki, H., Moriyama, S., Mizuno, K., Yukiue, H., Konishi, A., Yano, M., Kaji,
M., Fukai, I., Kiriyama, M., Yamakawa, Y., and Fujii, Y. (2003a). Cten mRNA
expression was correlated with tumor progression in lung cancers. Lung
Cancer 40, 151–155.
Sasaki, H., Yukiue, H., Kobayashi, Y., Fukai, I., and Fujii, Y. (2003b). Cten
mRNA expression is correlated with tumor progression in thymoma. Tumour
Biol. 24, 271–274.
Smolen, G.A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald,
H., Kim,W.J., Okimoto, R.A., Bell, D.W., Sgroi, D.C., et al. (2006). Amplification
of MET may identify a subset of cancers with extreme sensitivity to the selec-
tive tyrosine kinase inhibitor PHA-665752. Proc. Natl. Acad. Sci. USA 103,
2316–2321.436 Developmental Cell 29, 421–436, May 27, 2014 ª2014 Elsevier InStraussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J.,
Davis, A., Mongare, M.M., Gould, J., Frederick, D.T., et al. (2012). Tumour
micro-environment elicits innate resistance to RAF inhibitors through HGF
secretion. Nature 487, 500–504.
Trusolino, L., Bertotti, A., and Comoglio, P.M. (2010). MET signalling: princi-
ples and functions in development, organ regeneration and cancer. Nat.
Rev. Mol. Cell Biol. 11, 834–848.
Zhou, H.Y., Pon, Y.L., and Wong, A.S. (2008). HGF/MET signaling in ovarian
cancer. Curr. Mol. Med. 8, 469–480.
Zou, H.Y., Li, Q., Lee, J.H., Arango, M.E., McDonnell, S.R., Yamazaki, S.,
Koudriakova, T.B., Alton, G., Cui, J.J., Kung, P.P., et al. (2007). An orally avail-
able small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive
antitumor efficacy through antiproliferative and antiangiogenic mechanisms.
Cancer Res. 67, 4408–4417.c.
